Search Results - "Merims, S"

  • Showing 1 - 8 results of 8
Refine Results
  1. 1

    Informal caregiving to older cancer patients: preliminary research outcomes and implications by Goldzweig, G., Merims, S., Ganon, R., Peretz, T., Altman, A., Baider, L.

    Published in Annals of oncology (01-10-2013)
    “…The population of the Western world is aging while cancer survival rates are rising. Older patients with cancer will increasingly be taken care of by informal…”
    Get full text
    Journal Article
  2. 2

    Messenger RNA encoding constitutively active Toll‐like receptor 4 enhances effector functions of human T cells by Pato, A., Eisenberg, G., Machlenkin, A., Margalit, A., Cafri, G., Frankenburg, S., Merims, S., Peretz, T., Lotem, M., Gross, G.

    Published in Clinical and experimental immunology (01-11-2015)
    “…Summary Adoptive T cell therapy of cancer employs a large number of ex‐vivo‐propagated T cells which recognize their targets either by virtue of their…”
    Get full text
    Journal Article
  3. 3

    Anti-leukemia effect of ex vivo expanded DNT cells from AML patients: a potential novel autologous T-cell adoptive immunotherapy by Merims, S, Li, X, Joe, B, Dokouhaki, P, Han, M, Childs, R W, Wang, Z-Y, Gupta, V, Minden, M D, Zhang, L

    Published in Leukemia (01-09-2011)
    “…CD3 + CD56 − , CD4 and CD8 double negative T (DNT) cells comprise 1–3% of peripheral blood (PB) mononuclear cells. Their role in tumor immunity remains largely…”
    Get full text
    Journal Article
  4. 4

    Interleukin-2 improves tumour response to DNP-modified autologous vaccine for the treatment of metastatic malignant melanoma by LOTEM, M, SHILONI, E, PERETZ, T, PAPPO, I, DRIZE, O, HAMBURGER, T, WEITZEN, R, ISACSON, R, KADURI, L, MERIMS, S, FRANKENBURG, S

    Published in British journal of cancer (23-02-2004)
    “…This paper is a report of response rate (RR) and survival of 34 metastatic melanoma patients who received a dinitrophenyl (DNP)-modified autologous melanoma…”
    Get full text
    Journal Article
  5. 5
  6. 6

    MHC Class I-Independent Recognition of NK-Activating Receptor KIR2DS4 by Katz, Gil, Gazit, Roi, Arnon, Tal I, Gonen-Gross, Tsufit, Tarcic, Gabi, Markel, Gal, Gruda, Raizy, Achdout, Hagit, Drize, Olga, Merims, Sharon, Mandelboim, Ofer

    Published in The Journal of immunology (1950) (01-08-2004)
    “…Natural killer cells are capable of killing tumor and virus-infected cells. This killing is mediated primarily via the natural cytotoxicity receptors,…”
    Get full text
    Journal Article
  7. 7

    HLA-B35 correlates with a favorable outcome following adjuvant administration of an HLA-matched allogeneic melanoma vaccine by Lotem, M., Kadouri, L., Merims, S., Ospovat, I., Nissan, A., Ron, I., Frankenburg, S., Machlenkin, A., Israel, S., Steinberg, H., Hamburger, T., Peretz, T.

    Published in Tissue antigens (01-09-2011)
    “…This work presents survival data of 42 melanoma patients at high risk for disease recurrence who received an allogeneic melanoma vaccine composed of three cell…”
    Get full text
    Journal Article
  8. 8

    The validity of the Mathias criteria for establishing occupational causation and aggravation of contact dermatitis by Ingber, Arieh, Merims, Sharon

    Published in Contact dermatitis (01-07-2004)
    “…Mathias proposed 7 criteria for establishing occupational causation and aggravation of contact dermatitis (Mathias, J Am Acad Dermatol 1989, 20, 842–848). 4 of…”
    Get full text
    Journal Article